Metabolic and genetic predictors of circulating adipocyte fatty acid-binding protein

Tönjes, Anke; Kralisch, Susan; Lössner, Ulrike; Kovacs, Peter; Blüher, Matthias; Stümvoll, Michael; Faßhauer, Mathias

doi:10.1038/ijo.2011.162

Cited by 18 publications

(3 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All subjects are part of a sample from an extensively phenotyped self-contained population of Sorbs from Eastern Germany described in more detail recently (Tonjes et al 2009(Tonjes et al , 2010(Tonjes et al , 2012. At present, about 1000 Sorbs are enrolled in the study.…”

Section: Subjectsmentioning

confidence: 99%

Fibroblast growth factor-21 serum concentrations are associated with metabolic and hepatic markers in humans

Kralisch

Tönjes

Krause

et al. 2012

Journal of Endocrinology

View full text Add to dashboard Cite

Rather than a traditional growth factor, fibroblast growth factor-21 (FGF21) is considered to be a metabolic hormone. In the current study, we investigated serum FGF21 levels in the selfcontained population of Sorbs. Serum FGF21 concentrations were quantified by ELISA and correlated with IGF1 as well as metabolic, renal, hepatic, inflammatory, and cardiovascular parameters in 913 Sorbs from Germany. Moreover, human IGF1 protein secretion was investigated in FGF21-stimulated HepG2 cells. Median FGF21 serum concentrations were 2.1-fold higher in subjects with type 2 diabetes mellitus (141.8 ng/l) compared with controls (66.7 ng/l). Furthermore, nondiabetic subjects with FGF21 levels below the detection limit of the ELISA showed a more beneficial metabolic profile compared with subjects with measurable FGF21. Moreover, FGF21 was significantly lower in female compared with male subjects after adjustment for age and BMI. In multiple regression analyses, circulating FGF21 concentrations remained independently and positively associated with gender, systolic blood pressure, triglycerides, and g glutamyl transferase whereas a negative association was observed with IGF1 in nondiabetic subjects. Notably, FGF21 significantly inhibited IGF1 secretion into HepG2 cell culture supernatants in preliminary in vitro experiments. FGF21 serum concentrations are associated with facets of the metabolic syndrome, hepatocellular function, as well as GH status.

show abstract

Section: Subjectsmentioning

confidence: 99%

Fibroblast growth factor-21 serum concentrations are associated with metabolic and hepatic markers in humans

Kralisch

Tönjes

Krause

et al. 2012

Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…Most of these studies predate, or were on the cusp of, the era of genome-wide association studies and lacked robust study designs or methods, potentially leading to under-powered studies and irreproducible associations. Only a few GWAS were executed and reported on agnostically discovered common variants associated with FABP4 circulating levels [ 75 , 76 ]. Of course, biologically, it makes sense that common variants near or in any given gene, its transcription start site, or its enhancer regions, should modulate expression in the context of the Central Dogma where DNA encodes RNA that is translated to protein.…”

Section: Genetics Of Fabp4 In Humansmentioning

confidence: 99%

The Effects of FABP4 on Cardiovascular Disease in the Aging Population

van der Ark-Vonk,

Puijk,

Pasterkamp

et al. 2024

Curr Atheroscler Rep

View full text Add to dashboard Cite

Purpose of Review Fatty acid-binding protein 4 (FABP4) plays a role in lipid metabolism and cardiovascular health. In this paper, we cover FABP4 biology, its implications in atherosclerosis from observational studies, genetic factors affecting FABP4 serum levels, and ongoing drug development to target FABP4 and offer insights into future FABP4 research. Recent Findings FABP4 impacts cells through JAK2/STAT2 and c-kit pathways, increasing inflammatory and adhesion-related proteins. In addition, FABP4 induces angiogenesis and vascular smooth muscle cell proliferation and migration. FABP4 is established as a reliable predictive biomarker for cardiovascular disease in specific at-risk groups. Genetic studies robustly link PPARG and FABP4 variants to FABP4 serum levels. Considering the potential effects on atherosclerotic lesion development, drug discovery programs have been initiated in search for potent inhibitors of FABP4. Summary Elevated FABP4 levels indicate an increased cardiovascular risk and is causally related to acceleration of atherosclerotic disease, However, clinical trials for FABP4 inhibition are lacking, possibly due to concerns about available compounds’ side effects. Further research on FABP4 genetics and its putative causal role in cardiovascular disease is needed, particularly in aging subgroups.

show abstract

“…The SNPs rs1054135 , rs16909196 , and rs16909187 were among the genotyped SNPs. The rs16909187 polymorphism was found to have no effect on FAPB4 concentration in Sorbs from Germany [ 18 ].…”

Section: Introductionmentioning

confidence: 99%

Adipocyte “Fatty Acid Binding Protein” Gene Polymorphisms (rs1054135, rs16909196 and rs16909187) in Jordanians with Obesity and Type 2 Diabetes Mellitus

El-Ryalat

Irshaid

Abujbara³

et al. 2022

Balkan Journal of Medical Genetics

View full text Add to dashboard Cite

Background Obesity, type 2 diabetes mellitus (T2DM), and dyslipidemia may result from the interactions of genetic and environmental factors. There are controversial reports concerning the association of polymorphisms (rs1054135, rs16909196 and rs16909187) in the gene of adipocyte fatty acid binding protein (FABP4) with obesity and T2DM. Therefore, we designed this study to determine the association of these polymorphisms with obesity, T2DM, and dyslipidemia among Jordanian subjects. Methods The study was approved by the National Center for Diabetes, Endocrinology, and Genetics (NCDEG) Institutional Review Board (IRB). A total of 397 subjects were enrolled in the study and divided into four groups as described in materials and methods section. The fatty acid binding protein 4 (FABP4) gene containing (rs1054135, rs16909196 and rs16909187) single nucleotide polymorphisms (SNP) was amplified by polymerase chain reaction (PCR) followed by Sanger DNA sequencing of the PCR product. Results None of the three SNPs were associated with T2DM (p > 0.05). The rs16909187 and rs16909196 were significantly associated with obesity. The wild type (CC) of rs16909187 was significantly higher among the overweight and obese group compared with normal weight controls (OD = 2.17, 95% CI = 1.18 - 3.96, p =0.01). The wild type of rs16909196 (AA) was significantly higher among the overweight and obese group compared to controls, (OD = 2.26, 95% CI = 1.24 - 4.14, p = 0.01). These results may indicate that the wild-type may be a risk factor for obesity. Only the rs1054135 SNP was significantly associated with increased low density lipoprotein (LDL) levels in the overweight and obese group compared with the controls (p = 0.03). Conclusions The wild-type genotypes of rs16909196 and rs16909187 may be risk factors for obesity but not T2DM. None of the three SNPs was associated with T2DM.

show abstract

Metabolic and genetic predictors of circulating adipocyte fatty acid-binding protein

Cited by 18 publications

References 34 publications

Fibroblast growth factor-21 serum concentrations are associated with metabolic and hepatic markers in humans

Fibroblast growth factor-21 serum concentrations are associated with metabolic and hepatic markers in humans

The Effects of FABP4 on Cardiovascular Disease in the Aging Population

Adipocyte “Fatty Acid Binding Protein” Gene Polymorphisms (rs1054135, rs16909196 and rs16909187) in Jordanians with Obesity and Type 2 Diabetes Mellitus

Contact Info

Product

Resources

About